Beta Bionics (NASDAQ:BBNX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Beta Bionics (NASDAQ:BBNX) posted its quarterly earnings results on Tuesday. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01, FiscalAI reports. The company had revenue of $35.51 million for the quarter.

Here are the key takeaways from Beta Bionics’ conference call:

• Q3 net sales reached a record $35.5 million, up approximately 30% year over year, driven by new patient starts and recurring pharmacy-channel supply revenue. Gross margin rose to 57.3% year over year, despite unfavorable distributor inventory mix.
• FDA clearance for the Mint patch pump remains the company’s central catalyst, with full U.S. commercialization expected in Q1 2027. Management expects Mint coverage for about 40% of U.S. lives at launch and roughly 50% by year-end 2027, while targeting at least 1.5 million units of production capacity in 2027.
• Beta Bionics raised approximately $161 million in net proceeds, ending the quarter with about $374 million in cash, equivalents and investments. The company said the funds will support Mint manufacturing, commercialization and pipeline investments.
• Full-year 2026 revenue guidance was raised at the low end to $124 million-$126 million, reflecting lower-than-expected deferrals ahead of Mint’s launch. Management expects the deferred revenue to be more than recovered in 2027.
• The FDA requested withdrawal and resubmission of the 3D Intelligence 510(k), citing additional questions about validation of the simulator rather than concerns with the algorithm itself. Beta Bionics plans to resubmit in mid-Q4 2026, but now expects a U.S. launch around mid-2027, and Mint’s gross margin is expected to be dilutive in 2027.

Beta Bionics Trading Up 4.3%

BBNX stock opened at $21.39 on Wednesday. Beta Bionics has a 1 year low of $8.80 and a 1 year high of $32.71. The company has a fifty day simple moving average of $19.23 and a 200 day simple moving average of $14.97. The firm has a market cap of $962.34 million, a PE ratio of -12.96 and a beta of 3.39.

Insider Activity

In other Beta Bionics news, insider Steven Russell sold 4,221 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $80,663.31. Following the transaction, the insider directly owned 169,628 shares of the company’s stock, valued at $3,241,591.08. This represents a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,375 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $83,606.25. Following the transaction, the insider owned 180,040 shares in the company, valued at approximately $3,440,564.40. This trade represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 98,472 shares of company stock valued at $1,920,481. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC lifted its stake in shares of Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the last quarter. BlackRock Inc. acquired a new position in Beta Bionics in the 2nd quarter valued at $52,340,000. Bank of New York Mellon Corp acquired a new position in Beta Bionics in the 2nd quarter valued at $1,926,000. Squarepoint Ops LLC bought a new position in Beta Bionics in the 2nd quarter worth $2,524,000. Finally, Bruce & Co. Inc. bought a new position in Beta Bionics in the 1st quarter worth $5,518,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BBNX shares. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. The Goldman Sachs Group boosted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Bank of America upped their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Jefferies Financial Group began coverage on shares of Beta Bionics in a research note on Monday, October 12th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Barclays started coverage on Beta Bionics in a report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results modestly exceeded expectations: Beta Bionics reported an adjusted loss of $0.52 per share, narrowly beating the $0.53 consensus loss forecast, while revenue of $35.51 million topped the roughly $34.7 million estimate. Beta Bionics Reports Q3 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management held its third-quarter earnings call and updated full-year 2026 guidance. Investors will focus on the outlook for iLet demand, regulatory remediation, commercialization, and cash usage; the available reports do not provide enough detail to determine whether the guidance change is favorable. Beta Bionics Announces Third Quarter Results and Updates Guidance
• Negative Sentiment: Multiple law firms publicized a pending securities class action against Beta Bionics and certain executives. The complaints allege that the company failed to disclose or adequately characterize FDA concerns, including a June 2025 Form 483, a subsequent FDA Warning Letter, and more than 18,000 allegedly unreported iLet complaints. Investors who purchased shares between July 30, 2025, and February 24, 2026, face a November 3, 2026 lead-plaintiff deadline. The allegations have not been proven, but the litigation adds legal, reputational, regulatory, and potential financial risks. Beta Bionics Securities-Fraud Lawsuit

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.